ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone furoate - ספריי - fluticasone furoate 27.5 mcg/dose - fluticasone furoate - fluticasone - avamys (fluticasone furoate) nasal spray is indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients aged 2 years and older.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - תרחיף - fluticasone propionate 0.05 g / 100 g - fluticasone - fluticasone - prophylaxis and treatment of seasonal allergic rhinitis including hayfever, and perennial rhinitis. perenial rhinitis in children of the age of 4 years.

ישראל - עברית - Ministry of Health

trima israel pharmaceutical products maabarot ltd - fluticasone propionate - תרחיף - fluticasone propionate 0.05 %w/w - fluticasone - fluticasone - prophylaxis and treatment of seasonal allergic rhinitis including hay fever and perenial rhinitis.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.

ישראל - עברית - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - תרחיף בלחץ לשאיפה - fluticasone propionate 0.25 mg/dose; formoterol fumarate dihydrate 0.01 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting ?2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting ?2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting ?2 agonist.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - אבקה לשאיפה - fluticasone propionate 500 mcg - fluticasone - fluticasone - prophylactic management of all grades of asthma. symptomatic treatment of chronic obstructive pulmonary disease.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - אבקה לשאיפה - fluticasone propionate 250 mcg - fluticasone - fluticasone - prophylactic management of all grades of asthma. symptomatic treatment of chronic obstructive pulmonary disease.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - אבקה לשאיפה - fluticasone propionate 50 mcg - fluticasone - fluticasone - prophylactic management of all grades of asthma.

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - fluticasone propionate - תרחיף לשאיפה לערפול - fluticasone propionate 0.5 mg / 2 ml - fluticasone - fluticasone - in adults and adolescents over 16 years flixotide nebules can be used:for prophylactic management of severe chronic asthma in patients requiring high dose inhaled or oral corticosteroid therapy. it reduces symptoms and exacerbations of asthma in patients previously treated with other prophylactic therapy.children and adolescents from 4 to 16 years of age:treatment of acute exacerbations of asthma.